In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

NanoViricides, Inc.. Trade Record

AMEX:NNVC NanoViricides, Inc. stock gains 6.96% Exit Jan 4, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart NNVC Jan 3, 2019, priceSeries
About NanoViricides, Inc.

NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could enable a functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; anti-viral eye drops against external eye viral infections; and other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

Trade Information
Trade Type
LONG
ReliabilityScore™
88.55
Entry Date
Jan 3, 2019
Entry Price
5.60
Sell Date
Jan 4, 2019
Sell Price
5.99
Net Gain
6.96%
Hold Time
1 Trading Days